Literals
- aiiso:code
- ad7439a01a065ec2cd81bee6776da9f4
- ou:dialnetId
- 3311844
- foaf:firstName
- JESÚS
- ou:indiceHscopus
- 18
- foaf:lastName
- COBALEDA POLO
- foaf:name
- JESÚS COBALEDA POLO
- vivo:scopusId
- 6603259776
Typed Literals
- ou:esDoctor
- False (xsd:boolean)
- ou:personalActual
- False (xsd:boolean)
Relations
- teach:teacherOf
- ou:tienePublicacion
- Acetylator polymorphism in Parkinson's disease
- Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis
- Clinical implementation of pharmacogenetics and personalized drug prescription based on e-health: The MedeA initiative
- DEBRISOQUINE HYDROXYLATION PHENOTYPES IN HEALTHY VOLUNTEERS
- Debrisoquin and mephenytoin hydroxylation phenotypes and CΥP2D6 genotype in patients treated with neuroleptic and antidepressant agents
- Debrisoquin oxidation polymorphism in a Spanish population
- Debrisoquine oxidation phenotype in psychiatric patients.
- Debrisoquine oxidation in schizophrenic patients treated with neuroleptics
- Debrisoquine oxidation phenotype during neuroleptic monotherapy
- Debrisoquine oxidation phenotype during neuroleptic monotherapy
- Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: Application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship
- Evaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: The CEIBA cocktail
- Genomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans
- High frequency of CYP2D6 ultrarapid metabolizers in Spain: Controversy about their misclassification in worldwide population studies
- Increased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the CYP2C9*3 allele
- Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations
- Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain
- Interethnic differences in drug metabolism: Influence of genetic and environmental factors on debrisoquine hydroxylation phenotype
- Interethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and predicted drug metabolism phenotypes among 6060 ibero-and native Americans: RIBEF-CEIBA consortium report on population pharmacogenomics
- Oxidative polymorphism of debrisoquine in Parkinson's disease
- Pharmacogenetics in Latin American populations: Regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders
- Polymorphic oxidation of debrisoquine in lung cancer patients
- Polymorphic oxidation of debrisoquine in bladder cancer
- Relationship between personality and debrisoquine hydroxylation capacity: Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6
- Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population
- VEGF-related polymorphisms identified by GWAS and risk for major depression
- Validation of the telephone call as a method for measuring compliance to arterial hypertension treatment in Extremadura
- ou:perteneceAGrupoInvestigacion